RECODE · 연구동향생성일 2026-10-31

연구동향

기준 논문: Influence of the apolipoprotein E type 4 allele on cerebral glucose metabolism in Alzheimer's disease patients

J Neuropsychiatry Clin Neurosci 15(1):78-83 · 2003 · PMID 12556576

검색 방법

이 논문의 제목과 주제어를 바탕으로 이 논문이 속한 연구 분야를 묻는 질문을 만들어 ReviewFast에 넣어 2026-10-31에 검색했습니다. ReviewFast가 PubMed를 검색하고, AI 모델(Jev)이 제목과 초록을 읽어 질문과의 관련도를 매긴 뒤 주제별로 묶었습니다.

1,634편 검색→1,618편 판독→147편 선별 (관련도 0.5 이상)

질문과 PubMed 검색식 보기질문: Apolipoprotein E epsilon4 allele and cerebral glucose metabolism on PET in Alzheimer disease (("apolipoprotein E"[tiab] OR APOE[tiab] OR "apoE4"[tiab] OR "epsilon 4"[tiab] OR "epsilon4"[tiab] OR "ε4"[tiab] OR "APOE4"[tiab]) AND ("glucose metabolism"[tiab] OR "FDG"[tiab] OR "fluorodeoxyglucose"[tiab] OR "cerebral glucose"[tiab] OR "hypometabolism"[tiab] OR "PET"[tiab] OR "positron emission tomography"[tiab]) AND ("Alzheimer disease"[tiab] OR "Alzheimer's disease"[tiab] OR "Alzheimer"[tiab] OR "AD"[tiab]))

출판 연도

1995: 1편119951996: 2편21997: 2편21998: 3편32000: 1편120002001: 4편42002: 1편12003: 2편22004: 5편52005: 4편420052006: 2편22008: 4편42009: 1편12010: 7편720102011: 3편32012: 2편22013: 7편72014: 9편92015: 6편620152016: 12편122017: 7편72018: 9편92019: 7편72020: 10편1020202021: 6편62022: 6편62023: 5편52024: 7편72025: 5편52026: 7편72026

선별된 147편의 출판 연도. 검색일(2026-10-31) 기준이며, 그 이후 논문은 들어 있지 않습니다.

주제별 논문

주제 이름은 ReviewFast가 초록의 단어로 자동으로 붙인 것입니다. 왼쪽 숫자는 관련도(0–1)입니다. RECODE 는 우리 연구팀 논문입니다.

01regions · posterior cingulate79편

  1. 0.97

    Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease

    Mosconi L, Nacmias B, Sorbi S et al. · Journal of neurology, neurosurgery, and psychiatry · 2004

  2. 0.97

    Cerebral glucose metabolism in patients with AD and different APOE genotypes

    Drzezga A, Riemenschneider M, Strassner B et al. · Neurology · 2005

  3. 0.96

    Topographical APOE varepsilon4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer's Disease: Amyloid Burden Adjusted Analysis

    Seo EH, Kim SH, Park SH et al. · Journal of Alzheimer's disease : JAD · 2016

  4. 0.96

    Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and alpha1-antichymotrypsin type A allele in Alzheimer's disease

    Higuchi M, Arai H, Nakagawa T et al. · Neuroreport · 1997

  5. 0.95

    Influence of the apolipoprotein E type 4 allele on cerebral glucose metabolism in Alzheimer's disease patients 이 논문

    Lee KU, Lee JS, Kim KW et al. · The Journal of neuropsychiatry and clinical neurosciences · 2003

  6. 0.95

    The effect of APOE epsilon4 allele on cerebral glucose metabolism in AD is a function of age at onset

    Hirono N, Hashimoto M, Yasuda M et al. · Neurology · 2002

  7. 0.95

    The role of epsilon phenotype in brain glucose consumption in Alzheimer's disease

    Ricci M, Chiaravalloti A, Martorana A et al. · Annals of nuclear medicine · 2020

  8. 0.95

    Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients

    Lehmann M, Ghosh PM, Madison C et al. · Journal of neurology, neurosurgery, and psychiatry · 2014

  9. 0.95

    No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes

    Corder EH, Jelic V, Basun H et al. · Archives of neurology · 1997

  10. 0.95

    Lack of association of apolipoprotein E epsilon4 allele dose with cerebral glucose metabolism in Alzheimer disease

    Hirono N, Mori E, Yasuda M et al. · Alzheimer disease and associated disorders · 1998

  11. 0.95

    Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia

    Ossenkoppele R, van der Flier WM, Zwan MD et al. · Neurology · 2013

  12. 0.94

    Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve

    Mosconi L, Herholz K, Prohovnik I et al. · Journal of neurology, neurosurgery, and psychiatry · 2005

  13. 0.94

    Age and ApoE genotype interaction in Alzheimer's disease: an FDG-PET study

    Mosconi L, Sorbi S, Nacmias B et al. · Psychiatry research · 2004

  14. 0.94

    Apolipoprotein E polymorphism influences the cerebral metabolic pattern in Alzheimer's disease

    Mielke R, Zerres K, Uhlhaas S et al. · Neuroscience letters · 1998

  15. 0.93

    MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET

    Mosconi L, Perani D, Sorbi S et al. · Neurology · 2004

  16. 0.92

    The effect of ApoE epsilon4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study

    Paranjpe MD, Chen X, Liu M et al. · NeuroImage. Clinical · 2019

  17. 0.92

    Association between an Alzheimer's Disease-Related Index and APOE epsilon4 Gene Dose

    Schraml F, Chen K, Ayutyanont N et al. · PloS one · 2013

  18. 0.92

    Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele

    Langbaum JBS, Chen K, Caselli RJ et al. · Archives of neurology · 2010

  19. 0.90

    Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia

    Reiman EM, Chen K, Alexander GE et al. · Proceedings of the National Academy of Sciences of the United States of America · 2004

  20. 0.90

    Sex difference in the association of APOE4 with cerebral glucose metabolism in older adults reporting significant memory concern

    Jiang L, Lin H, Alzheimer's Disease Neuroimaging Initiative et al. · Neuroscience letters · 2020

  21. 0.90

    Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E

    Reiman EM, Caselli RJ, Yun LS et al. · The New England journal of medicine · 1996

  22. 0.89

    Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease

    Reiman EM, Uecker A, Caselli RJ et al. · Annals of neurology · 1998

  23. 0.89

    Education and occupation provide reserve in both ApoE epsilon4 carrier and noncarrier patients with probable Alzheimer's disease

    Garibotto V, Borroni B, Sorbi S et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2012

  24. 0.89

    Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease

    Small GW, Ercoli LM, Silverman DH et al. · Proceedings of the National Academy of Sciences of the United States of America · 2000

  25. 0.88

    Modulation of glucose metabolism and metabolic connectivity by beta-amyloid

    Carbonell F, Zijdenbos AP, McLaren DG et al. · Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2016

  26. 0.88

    beta-Amyloid is associated with aberrant metabolic connectivity in subjects with mild cognitive impairment

    Carbonell F, Charil A, Zijdenbos AP et al. · Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2014

  27. 0.87

    The effect of beta-amyloid positivity on cerebral metabolism in cognitively normal seniors

    Bozoki AC, Zdanukiewicz M, Zhu DC · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2016

  28. 0.87

    A FDG-PET Study of Metabolic Networks in Apolipoprotein E epsilon4 Allele Carriers

    Yao Z, Hu B, Zheng J et al. · PloS one · 2015

  29. 0.85

    Tau-related reduction of glucose metabolism in mild cognitive impairment occurs independently of APOE epsilon4 genotype and is influenced by Abeta

    Carbonell F, McNicoll C, Zijdenbos AP et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

  30. 0.85

    Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients

    Stefanova E, Blennow K, Almkvist O et al. · Neuroscience letters · 2003

  31. 0.85

    Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism

    Darreh-Shori T, Brimijoin S, Kadir A et al. · Neurobiology of disease · 2006

  32. 0.85

    Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

    Langbaum JBS, Chen K, Lee W et al. · NeuroImage · 2009

  33. 0.84

    APOE4 and Infectious Diseases Jointly Contribute to Brain Glucose Hypometabolism, a Biomarker of Alzheimer's Pathology: New Findings from the ADNI

    Rajendrakumar AL, Arbeev KG, Bagley O et al. · medRxiv : the preprint server for health sciences · 2024

  34. 0.84

    Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment

    Blautzik J, Kotz S, Brendel M et al. · Journal of Alzheimer's disease : JAD · 2018

  35. 0.84

    Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging

    Jagust WJ, Landau SM · The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012

  36. 0.83

    Effects of baseline serum uric acid and apolipoprotein E4 on longitudinal cognition and cerebral metabolism

    Lee YG, Park M, Jeong SH et al. · Neurobiology of aging · 2021

  37. 0.82

    Perceived loss of memory ability and cerebral metabolic decline in persons with the apolipoprotein E-IV genetic risk for Alzheimer disease

    Ercoli L, Siddarth P, Huang SC et al. · Archives of general psychiatry · 2006

  38. 0.82

    Synergistic interaction between APOE and family history of Alzheimer's disease on cerebral amyloid deposition and glucose metabolism

    Yi D, Lee Y, Byun MS et al. · Alzheimer's research & therapy · 2018

  39. 0.82

    Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism

    Reiman EM, Chen K, Alexander GE et al. · Proceedings of the National Academy of Sciences of the United States of America · 2005

  40. 0.81

    Association between GAB2 haplotype and higher glucose metabolism in Alzheimer's disease-affected brain regions in cognitively normal APOEepsilon4 carriers

    Liang WS, Chen K, Lee W et al. · NeuroImage · 2011

  41. 0.81

    Beta-amyloid associated differential effects of APOE epsilon4 on brain metabolism in cognitively normal elderly

    Yi D, Lee DY, Sohn BK et al. · The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2014

  42. 0.80

    Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease

    Reiman EM, Caselli RJ, Chen K et al. · Proceedings of the National Academy of Sciences of the United States of America · 2001

  43. 0.80

    APOE4 and infectious diseases jointly contribute to brain glucose hypometabolism, a biomarker of Alzheimer's pathology: New findings from the ADNI

    Lathika Rajendrakumar A, Arbeev KG, Bagley O et al. · PloS one · 2025

  44. 0.79

    Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders

    Durazzo TC, Mattsson N, Weiner MW · Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2016

  45. 0.78

    Atypical Localization and Dissociation between Glucose Uptake and Amyloid Deposition in Cognitively Normal APOE*E4 Homozygotic Elders Compared with Patients with Late-Onset Alzheimer's Disease

    Pardo JV, Lee JT · eNeuro · 2018

  46. 0.77

    Patterns of Glucose Metabolism in [ (18) F]FDG PET Indicate Regional Variability and Neurodegeneration in the Progression of Alzheimer's Dementia

    Lee JJ, Earnest T, Ha SM et al. · medRxiv : the preprint server for health sciences · 2023

  47. 0.77

    Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions

    Reiman EM, Chen K, Caselli RJ et al. · NeuroImage · 2008

  48. 0.76

    Imaging and cognitive reserve studies predict dementia in presymptomatic Alzheimer's disease subjects

    Ferrari C, Nacmias B, Bagnoli S et al. · Neuro-degenerative diseases · 2014

  49. 0.75

    Fluoro-2-deoxy-D-glucose (FDG)-PET in APOEepsilon4 carriers in the Australian population

    Rimajova M, Lenzo NP, Wu JS et al. · Journal of Alzheimer's disease : JAD · 2008

  50. 0.75

    A new data analysis approach for measuring longitudinal changes of metabolism in cognitively normal elderly adults

    Shokouhi S, Riddle WR, Kang H · Clinical interventions in aging · 2017

  51. 0.74

    18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons

    Knopman DS, Jack CRJ, Wiste HJ et al. · Neurobiology of aging · 2014

  52. 0.72

    Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET)

    de Leon MJ, Convit A, Wolf OT et al. · Proceedings of the National Academy of Sciences of the United States of America · 2001

  53. 0.71

    Brain Connectome Imaging Markers Research of Glucose Metabolism in the Early Stage of Alzheimer's Disease

    Zhang Q, Wang L, Han Y et al. · Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference · 2023

  54. 0.71

    Multi-modal imaging predicts memory performance in normal aging and cognitive decline

    Walhovd KB, Fjell AM, Dale AM et al. · Neurobiology of aging · 2010

  55. 0.70

    Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease

    Small GW, Mazziotta JC, Collins MT et al. · JAMA · 1995

  56. 0.69

    Genetic associations of in vivo pathology influence Alzheimer's disease susceptibility

    Seo J, Byun MS, Yi D et al. · Alzheimer's research & therapy · 2020

  57. 0.69

    Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology

    Laforce RJ, Tosun D, Ghosh P et al. · NeuroImage. Clinical · 2014

  58. 0.69

    Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging

    Reiman EM, Chen K, Langbaum JBS et al. · NeuroImage · 2010

  59. 0.69

    Personality factors and cerebral glucose metabolism in community-dwelling older adults

    Sohrabi HR, Goozee K, Weinborn M et al. · Brain structure & function · 2020

  60. 0.69

    Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment

    Caselli RJ, Chen K, Lee W et al. · Archives of neurology · 2008

  61. 0.68

    Influence of Hypertension on Longitudinal Changes in Brain Glucose Metabolism Was Modified by the APOE4 Allele Among Cognitively Normal Older Individuals

    Zhou R, Chen H, Ye F et al. · Frontiers in aging neuroscience · 2020

  62. 0.68

    A Case with Early Onset Alzheimer's Disease, Frontotemporal Hypometabolism, ApoE Genotype varepsilon4/varepsilon4 and C9ORF72 Intermediate Expansion: A Treviso Dementia (TREDEM) Registry Case Report

    Gallucci M, Dell'Acqua C, Bergamelli C et al. · Journal of Alzheimer's disease : JAD · 2019

  63. 0.67

    Plasma Apolipoprotein E3 and Glucose Levels Are Associated in APOE varepsilon3/varepsilon4 Carriers

    Edlund AK, Chen K, Lee W et al. · Journal of Alzheimer's disease : JAD · 2021

  64. 0.64

    Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease

    Ossenkoppele R, Schonhaut DR, Scholl M et al. · Brain : a journal of neurology · 2016

  65. 0.64

    Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease

    Abdelmoity O, Wisch JK, Kennedy JT et al. · Annals of neurology · 2025

  66. 0.63

    Peripheral apoE isoform levels in cognitively normal APOE epsilon3/epsilon4 individuals are associated with regional gray matter volume and cerebral glucose metabolism

    Nielsen HM, Chen K, Lee W et al. · Alzheimer's research & therapy · 2017

  67. 0.63

    Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients

    Almkvist O, Jelic V, Amberla K et al. · Dementia and geriatric cognitive disorders · 2001

  68. 0.62

    Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease

    Protas HD, Chen K, Langbaum JBS et al. · JAMA neurology · 2013

  69. 0.62

    APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls

    Sampedro F, Vilaplana E, de Leon MJ et al. · Oncotarget · 2015

  70. 0.61

    Sex-specific effect of cortisol on cerebral glucose metabolism across Alzheimer's disease spectrum: a neuroimaging study

    Alqarni A, Alkhybari E, Alshuhri MS et al. · Frontiers in neurology · 2026

  71. 0.61

    Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints

    Mosconi L, De Santi S, Brys M et al. · Biological psychiatry · 2008

  72. 0.61

    GWAS-Linked Loci and Neuroimaging Measures in Alzheimer's Disease

    Li JQ, Wang HF, Zhu XC et al. · Molecular neurobiology · 2017

  73. 0.61

    Omega-3 blood biomarkers relate to brain glucose uptake in individuals at risk of Alzheimer's disease dementia

    Lazaro I, Grau-Rivera O, Suarez-Calvet M et al. · Alzheimer's & dementia (Amsterdam, Netherlands) · 2024

  74. 0.59

    In Alzheimer-prone brain regions, metabolism and risk-gene expression are strongly correlated

    Ye F, Funk Q, Rockers E et al. · Brain communications · 2022

  75. 0.58

    Effect of APOE epsilon4 genotype on amyloid-beta, glucose metabolism, and gray matter volume in cognitively normal individuals and amnestic mild cognitive impairment

    Li W, Li R, Yan S et al. · European journal of neurology · 2023

  76. 0.56

    Longitudinal Changes in Serum Glucose Levels are Associated with Metabolic Changes in Alzheimer's Disease Related Brain Regions

    Burns CM, Kaszniak AW, Chen K et al. · Journal of Alzheimer's disease : JAD · 2018

  77. 0.56

    The effect of the top 20 Alzheimer disease risk genes on gray-matter density and FDG PET brain metabolism

    Stage E, Duran T, Risacher SL et al. · Alzheimer's & dementia (Amsterdam, Netherlands) · 2016

  78. 0.53

    Peripheral versus Central Index of Metabolic Dysfunction and Associations with Clinical and Pathological Outcomes in Alzheimer's Disease

    McLimans KE, Webb JL, Anantharam V et al. · Journal of Alzheimer's disease : JAD · 2017

  79. 0.50

    Rhinal hypometabolism on FDG PET in healthy APO-E4 carriers: impact on memory function and metabolic networks

    Didic M, Felician O, Gour N et al. · European journal of nuclear medicine and molecular imaging · 2015

02mild cognitive · mci24편

  1. 0.86

    Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET

    Drzezga A, Grimmer T, Riemenschneider M et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2005

  2. 0.81

    Predicting Alzheimer's disease with practice effects, APOE genotype and brain metabolism

    Oltra-Cucarella J, Sanchez-SanSegundo M, Ferrer-Cascales R · Neurobiology of aging · 2022

  3. 0.79

    Isolated medial temporal lobe amnesia (MTLA): Predictor of cerebral amyloidosis or marker of phenotype-specific vulnerability?

    Pin G, Horowitz T, Guedj E et al. · Revue neurologique · 2026

  4. 0.75

    Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia

    Arbizu J, Prieto E, Martinez-Lage P et al. · European journal of nuclear medicine and molecular imaging · 2013

  5. 0.73

    Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology

    Schreiber S, Schreiber F, Lockhart SN et al. · JAMA neurology · 2017

  6. 0.73

    Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients

    Choo IH, Ni R, Scholl M et al. · Journal of Alzheimer's disease : JAD · 2013

  7. 0.72

    FDG-PET markers of heterogeneity and different risk of progression in amnestic MCI

    Caminiti SP, De Francesco S, Tondo G et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024

  8. 0.70

    Longitudinal change of biomarkers in cognitive decline

    Lo RY, Hubbard AE, Shaw LM et al. · Archives of neurology · 2011

  9. 0.69

    Development of prediction models for distinguishable cognitive trajectories in patients with amyloid positive mild cognitive impairment

    Kim SJ, Woo SY, Kim YJ et al. · Neurobiology of aging · 2022

  10. 0.62

    Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers

    Jang H, Park J, Woo S et al. · NeuroImage. Clinical · 2019

  11. 0.59

    Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET

    Shokouhi S, Claassen D, Kang H et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2013

  12. 0.58

    Prediction and Classification of Alzheimer's Disease Based on Combined Features From Apolipoprotein-E Genotype, Cerebrospinal Fluid, MR, and FDG-PET Imaging Biomarkers

    Gupta Y, Lama RK, Kwon GR · Frontiers in computational neuroscience · 2019

  13. 0.58

    Classification and Graphical Analysis of Alzheimer's Disease and Its Prodromal Stage Using Multimodal Features From Structural, Diffusion, and Functional Neuroimaging Data and the APOE Genotype

    Gupta Y, Kim JI, Kim BC et al. · Frontiers in aging neuroscience · 2020

  14. 0.56

    Protective Factors Modulate the Risk of Beta Amyloid in Alzheimer's Disease

    Zhou B, Tanabe K, Kojima S et al. · Behavioural neurology · 2020

  15. 0.55

    Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression

    Caroli A, Prestia A, Galluzzi S et al. · Neurology · 2015

  16. 0.55

    Artificial neural networks identify the predictive values of risk factors on the conversion of amnestic mild cognitive impairment

    Tabaton M, Odetti P, Cammarata S et al. · Journal of Alzheimer's disease : JAD · 2010

  17. 0.55

    Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers

    Dukart J, Sambataro F, Bertolino A · Journal of Alzheimer's disease : JAD · 2016

  18. 0.54

    The Transition of Mild Cognitive Impairment Over Time: An AV45- and FDG-PET Study of Reversion and Conversion Phenomena

    Ashraf-Ganjouei A, Moradi K, Faghani S et al. · Current Alzheimer research · 2021

  19. 0.54

    The prevalence and biomarkers' characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database

    Ba M, Li X, Ng KP et al. · Alzheimer's & dementia (New York, N. Y.) · 2017

  20. 0.53

    Prediction of Mild Cognitive Impairment Conversion Using a Combination of Independent Component Analysis and the Cox Model

    Liu K, Chen K, Yao L et al. · Frontiers in human neuroscience · 2017

  21. 0.53

    Comparing predictors of conversion and decline in mild cognitive impairment

    Landau SM, Harvey D, Madison CM et al. · Neurology · 2010

  22. 0.51

    The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort

    Caroli A, Frisoni GB · Neurobiology of aging · 2010

  23. 0.50

    Modeling autosomal dominant Alzheimer's disease with machine learning

    Luckett PH, McCullough A, Gordon BA et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021

  24. 0.50

    Abnormal FDG-PET Patterns and Amyloid Positivity Predict Personality Changes in Cognitively Preserved Individuals

    Rodriguez C, Montandon ML, Garibotto V et al. · Brain sciences · 2026

03deposition · cognitively normal17편

  1. 0.90

    Genetic interaction is associated with lower metabolic connectivity and memory impairment in clinically mild Alzheimer's disease

    Chang YT, Huang CW, Huang SH et al. · Genes, brain, and behavior · 2019

  2. 0.85

    Metabolic brain networks in aging and preclinical Alzheimer's disease

    Arnemann KL, Stober F, Narayan S et al. · NeuroImage. Clinical · 2018

  3. 0.83

    Influence of APOE genotype on whole-brain functional networks in cognitively normal elderly

    Seo EH, Lee DY, Lee JM et al. · PloS one · 2013

  4. 0.83

    Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer's Disease and Cognitive Decline

    Stonnington CM, Velgos SN, Chen Y et al. · Journal of Alzheimer's disease : JAD · 2020

  5. 0.79

    Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo

    Darreh-Shori T, Forsberg A, Modiri N et al. · Neurobiology of aging · 2011

  6. 0.78

    APOE-dependent PET patterns of brain activation in Alzheimer disease

    Scarmeas N, Anderson KE, Hilton J et al. · Neurology · 2004

  7. 0.76

    Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study

    Vemuri P, Lesnick TG, Przybelski SA et al. · Neurology · 2016

  8. 0.75

    Regional patterns of gray matter volume, hypometabolism, and beta-amyloid in groups at risk of Alzheimer's disease

    Wirth M, Bejanin A, La Joie R et al. · Neurobiology of aging · 2018

  9. 0.74

    Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network

    Bussy A, Snider BJ, Coble D et al. · Neurobiology of aging · 2019

  10. 0.74

    Midlife Lifestyle Activities Moderate APOE epsilon4 Effect on in vivo Alzheimer's Disease Pathologies

    Jeon SY, Byun MS, Yi D et al. · Frontiers in aging neuroscience · 2020

  11. 0.69

    Apolipoprotein E varepsilon4-related effects on cognition are limited to the Alzheimer's disease spectrum

    Fernandez A, Vaquero L, Bajo R et al. · GeroScience · 2022

  12. 0.67

    Contributions of connectional pathways to shaping Alzheimer's disease pathologies

    Bougacha S, Roquet D, Landeau B et al. · Brain communications · 2025

  13. 0.64

    Alzheimer's disease genetic risk score and neuroimaging in the FINGER lifestyle trial

    Saadmaan G, Dalmasso MC, Ramirez A et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024

  14. 0.60

    Plasma NfL is associated with the APOE epsilon4 allele, brain imaging measurements of neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-aged and older adults

    Malek-Ahmadi M, Su Y, Ghisays V et al. · Alzheimer's research & therapy · 2023

  15. 0.56

    Effects of APOE epsilon2 on the Fractional Amplitude of Low-Frequency Fluctuation in Mild Cognitive Impairment: A Study Based on the Resting-State Functional MRI

    Liu X, Zeng Q, Luo X et al. · Frontiers in aging neuroscience · 2021

  16. 0.53

    Nutrient intake and brain biomarkers of Alzheimer's disease in at-risk cognitively normal individuals: a cross-sectional neuroimaging pilot study

    Mosconi L, Murray J, Davies M et al. · BMJ open · 2014

  17. 0.52

    Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease

    Besson FL, La Joie R, Doeuvre L et al. · The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015

04tau · temporal9편

  1. 0.93

    Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum

    Liu Y, Tan L, Wang HF et al. · Molecular neurobiology · 2016

  2. 0.84

    Association of Apolipoprotein E varepsilon4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults

    Ramanan VK, Castillo AM, Knopman DS et al. · JAMA network open · 2019

  3. 0.77

    Imaging and cerebrospinal fluid biomarkers in the search for Alzheimer's disease mechanisms

    Osorio RS, Pirraglia E, Gumb T et al. · Neuro-degenerative diseases · 2014

  4. 0.77

    Effects of APOE epsilon4 and amyloid pathology on longitudinal tau biomarkers, neurodegeneration, and cognitive decline in mild cognitive impairment

    Wang X, Zhang C, Liu X et al. · Journal of Alzheimer's disease : JAD · 2026

  5. 0.76

    APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern

    Risacher SL, Kim S, Nho K et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015

  6. 0.74

    Valine modulates Alzheimer's disease risk in APOE epsilon4 carriers: evidence from two cohorts

    Yang ZL, Zhang C, Tang S et al. · Journal of advanced research · 2026

  7. 0.73

    Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease

    Strom A, Iaccarino L, Edwards L et al. · Brain : a journal of neurology · 2022

  8. 0.70

    Do Cardiometabolic Risk Factors Influence Amyloid, Tau, and Neuronal Function in APOE4 Carriers and Non-Carriers in Alzheimer's Disease Trajectory?

    Femminella GD, Taylor-Davies G, Scott J et al. · Journal of Alzheimer's disease : JAD · 2018

  9. 0.61

    Association of Apolipoprotein E varepsilon4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome

    Bejanin A, Iulita MF, Vilaplana E et al. · JAMA neurology · 2021

05genetic · treatment8편

  1. 0.73

    DIAGNOSIS-GUIDED METHOD FOR IDENTIFYING MULTI-MODALITY NEUROIMAGING BIOMARKERS ASSOCIATED WITH GENETIC RISK FACTORS IN ALZHEIMER'S DISEASE

    Hao X, Yan J, Yao X et al. · Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2016

  2. 0.71

    Identifying Multimodal Intermediate Phenotypes Between Genetic Risk Factors and Disease Status in Alzheimer's Disease

    Hao X, Yao X, Yan J et al. · Neuroinformatics · 2016

  3. 0.64

    Longevity and cognitive resilience in a Colombian family carrying the APOE epsilon2 variant

    Guerrero A, Galvis-Garrido ND, Bocanegra Y et al. · Journal of Alzheimer's disease : JAD · 2026

  4. 0.57

    Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease

    Small GW · The Journal of clinical psychiatry · 1996

  5. 0.56

    The influence of bapineuzumab and semagacestat on rapid progressors: A retrospective cohort study

    Harris K, Shyer M, Wang D et al. · The journal of prevention of Alzheimer's disease · 2026

  6. 0.56

    Genetic-based patient stratification in Alzheimer's disease

    Hernandez-Lorenzo L, Garcia-Gutierrez F, Solbas-Casajus A et al. · Scientific reports · 2024

  7. 0.53

    Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes

    Townley RA, Graff-Radford J, Mantyh WG et al. · Brain communications · 2020

  8. 0.52

    GC-CNNnet: Diagnosis of Alzheimer's Disease with PET Images Using Genetic and Convolutional Neural Network

    Amini M, Pedram MM, Moradi A et al. · Computational intelligence and neuroscience · 2022

06metabolic · lipid5편

  1. 0.84

    Elevated blood glucose levels are associated with the progression of brain hypometabolism, and HDL-C and APOE4 add to this association

    Rajendrakumar AL, Ukraintseva S, Bagley O et al. · medRxiv : the preprint server for health sciences · 2024

  2. 0.79

    Identification of an APOE epsilon4-specific blood-based molecular pathway for Alzheimer's disease risk

    Tao Q, Zhang C, Mercier G et al. · Alzheimer's & dementia (Amsterdam, Netherlands) · 2023

  3. 0.61

    Alterations in cerebral perfusion and substrate metabolism in type 2 diabetes: interactions with APOE-epsilon4

    Schain M, Johansson E, Laitinen I et al. · Diabetologia · 2025

  4. 0.55

    Assessment of neurovascular uncoupling: APOE status is a key driver of early metabolic and vascular dysfunction

    Onos KD, Lin PB, Pandey RS et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024

  5. 0.50

    Brain energy metabolism in Alzheimer's disease: 99mTc-HMPAO SPECT imaging during verbal fluency and role of astrocytes in the cellular mechanism of 99mTc-HMPAO retention

    Slosman DO, Ludwig C, Zerarka S et al. · Brain research. Brain research reviews · 2001

07older · burden4편

  1. 0.91

    Sex differences in the association between apolipoprotein E epsilon4 allele and Alzheimer's disease markers

    Sundermann EE, Tran M, Maki PM et al. · Alzheimer's & dementia (Amsterdam, Netherlands) · 2018

  2. 0.61

    Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study

    Mosconi L, Rahman A, Diaz I et al. · PloS one · 2018

  3. 0.50

    Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community

    Petersen RC, Wiste HJ, Weigand SD et al. · JAMA neurology · 2016

  4. 0.50

    Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study

    Jack CRJ, Wiste HJ, Weigand SD et al. · The Lancet. Neurology · 2014

08plasma · biomarkers1편

  1. 0.75

    Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study

    Degerman Gunnarsson M, Lindau M, Wall A et al. · Dementia and geriatric cognitive disorders · 2010